dobutamine or milrinone

This entry refers to the use of either dobutamine or milrinone as positive inotropic agents for acute decompensated heart failure and cardiogenic shock. Both drugs are used intravenously for short-term management of patients with low cardiac output states. Dobutamine is a synthetic catecholamine that acts primarily as a beta-1 adrenergic receptor agonist, increasing myocardial contractility and cardiac output with some vasodilatory effects due to beta-2 activity. Milrinone is a phosphodiesterase 3 inhibitor that increases intracellular cAMP, leading to increased inotropy (contractility), lusitropy (relaxation), and significant peripheral vasodilation. While both improve hemodynamics rapidly, they differ in pharmacokinetics—dobutamine has a very short half-life (~2 minutes) while milrinone’s half-life is longer (~2.4 hours). Clinical studies show similar efficacy and safety profiles between the two drugs; choice often depends on patient-specific factors such as pulmonary hypertension or risk of arrhythmias[4][6][7].

Brand names

DobutrexPrimacor